Phoenix Eagle is a biopharmaceutical company developing disruptive technologies for the global wound healing and skin care markets.
We are a privately-held company founded in 2002. We have a pipeline of next-generation pharmaceutical and cosmetic / cosmeceutical products for treating and preventing skin disorders including non-healing ulcers and burns, and skin tears in fragile skin.
Our product pipeline is based around our unique OPAL technology which is protected by a strong global intellectual property position. Our lead therapeutic product is OPAL A.
Our Research and Development (non-clinical and clinical) has been undertaken in Australia and the United Kingdom. Our collaborators in the United States and Italy are planning studies on OPAL A and its variants.